Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Research & Development (2016 - 2026)

Ocular Therapeutix has reported Research & Development over the past 14 years, most recently at $66.2 million for Q1 2026.

  • For Q1 2026, Research & Development rose 54.5% year-over-year to $66.2 million; the TTM value through Mar 2026 reached $220.5 million, up 47.21%, while the annual FY2025 figure was $197.1 million, 54.42% up from the prior year.
  • Research & Development for Q1 2026 was $66.2 million at Ocular Therapeutix, up from $50.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $66.2 million in Q1 2026 and troughed at $13.1 million in Q1 2022.
  • A 5-year average of $29.7 million and a median of $20.7 million in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: decreased 5.48% in 2022 and later skyrocketed 153.1% in 2024.
  • Year by year, Research & Development stood at $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then skyrocketed by 153.1% to $41.0 million in 2024, then grew by 23.94% to $50.8 million in 2025, then skyrocketed by 30.34% to $66.2 million in 2026.
  • Business Quant data shows Research & Development for OCUL at $66.2 million in Q1 2026, $50.8 million in Q4 2025, and $52.4 million in Q3 2025.